TRACON Pharmaceuticals, Inc. (TCON) Scheduled to Post Quarterly Earnings on Monday
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.
TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.12. The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.81 million. TRACON Pharmaceuticals had a negative return on equity of 119.93% and a negative net margin of 963.11%. On average, analysts expect TRACON Pharmaceuticals to post $-1.55 EPS for the current fiscal year and $-1.01 EPS for the next fiscal year.
Shares of TRACON Pharmaceuticals, Inc. (NASDAQ TCON) opened at 2.65 on Monday. TRACON Pharmaceuticals, Inc. has a 12 month low of $2.00 and a 12 month high of $7.30. The company’s market capitalization is $44.14 million. The stock has a 50 day moving average price of $3.32 and a 200-day moving average price of $3.32.
Separately, Zacks Investment Research upgraded TRACON Pharmaceuticals from a “sell” rating to a “hold” rating and set a $2.50 price target on the stock in a report on Saturday, August 12th.
TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/30/tracon-pharmaceuticals-inc-tcon-scheduled-to-post-quarterly-earnings-on-monday.html.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.